FLT3 and acute myeloid leukemia: In an analysis of 513 patients with newly diagnosed AML, 96 patients with FLT3-ITD mutations experienced survival comparable with other patients with intermediate-risk features, and neither co-mutations in NPM1 nor FLT3-ITD AR influenced outcomes [87].